243 related articles for article (PubMed ID: 36710358)
1. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer.
Liu C; Li X; Huang Q; Zhang M; Lei T; Wang F; Zou W; Huang R; Hu X; Wang C; Zhang X; Sun B; Xing L; Yue J; Yu J
Signal Transduct Target Ther; 2023 Jan; 8(1):44. PubMed ID: 36710358
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Hecht M; Büttner-Herold M; Erlenbach-Wünsch K; Haderlein M; Croner R; Grützmann R; Hartmann A; Fietkau R; Distel LV
Eur J Cancer; 2016 Sep; 65():52-60. PubMed ID: 27468145
[TBL] [Abstract][Full Text] [Related]
3. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
4. Comparative Analysis of the Antitumor Immune Profiles of Paired Radiotherapy-naive and Radiotherapy-treated Cervical Cancer Tissues.
Imamura A; Oike T; Sato H; Yoshimoto Y; Ando K; Ohno T
Anticancer Res; 2022 Jul; 42(7):3341-3348. PubMed ID: 35790266
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Niu M; Combs SE; Linge A; Krause M; Baumann M; Lohaus F; Ebert N; Tinhofer I; Budach V; von der Grün J; Rödel F; Grosu AL; Multhoff G
Radiat Oncol; 2021 Jul; 16(1):141. PubMed ID: 34332614
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer.
Dorta-Estremera S; Colbert LE; Nookala SS; Yanamandra AV; Yang G; Delgado A; Mikkelson M; Eifel P; Jhingran A; Lilie LL; Welsh J; Schmeler K; Sastry JK; Klopp A
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):593-600. PubMed ID: 30017792
[TBL] [Abstract][Full Text] [Related]
7. Effects of retinoic acid on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Pecorelli S; Parham GP
Eur J Gynaecol Oncol; 1998; 19(3):229-33. PubMed ID: 9641219
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA-sequencing dissects cellular heterogeneity and identifies two tumor-suppressing immune cell subclusters in HPV-related cervical adenosquamous carcinoma.
Li X; Zhang M; Lei T; Zou W; Huang R; Wang F; Huang Q; Wang C; Liu C
J Med Virol; 2022 Dec; 94(12):6047-6059. PubMed ID: 36000446
[TBL] [Abstract][Full Text] [Related]
9. Local immune response in squamous cell carcinoma of the uterine cervix.
Hachisuga T; Fukuda K; Kawarabayashi T
Gynecol Obstet Invest; 2001; 52(1):3-8. PubMed ID: 11549855
[TBL] [Abstract][Full Text] [Related]
10. The Association between Epidermal Growth Factor Receptor Single Nucleotide Polymorphisms and Radiochemotherapy Response in Cervical Cancer.
Jin G; Fan XM; Li KX; Niu SH; Zhang QY
Pathol Oncol Res; 2020 Apr; 26(2):1255-1261. PubMed ID: 31254173
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of concurrent radiochemotherapy in cervical cancer and comparison of ultrasonography findings before and after radiochemotherapy.
Yan WM; Li XZ; Yu ZL; Zhang J; Sun XG
Genet Mol Res; 2015 Apr; 14(2):3633-9. PubMed ID: 25966132
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of selected MHC class I and II molecule expression in the course of HPV positive CIN treatment with the use of human recombinant IFN-gamma.
Sikorski M; Bobek M; Zrubek H; Marcinkiewicz J
Acta Obstet Gynecol Scand; 2004 Mar; 83(3):299-307. PubMed ID: 14995928
[TBL] [Abstract][Full Text] [Related]
13. Is there a benefit for adjuvant radio(chemo)therapy in early cervical cancer? Results from a population-based study.
Scharl S; Becher C; Gerken M; Scharl A; Anapolski M; Ignatov A; Inwald EC; Ortmann O; Kölbl O; Klinkhammer-Schalke M; Papathemelis T
Arch Gynecol Obstet; 2021 Sep; 304(3):759-771. PubMed ID: 33575846
[TBL] [Abstract][Full Text] [Related]
14. Swainsonine, an alpha-mannosidase inhibitor, may worsen cervical cancer progression through the increase in myeloid derived suppressor cells population.
Silveira CRF; Cipelli M; Manzine C; Rabelo-Santos SH; Zeferino LC; Rodríguez Rodríguez G; de Assis JB; Hebster S; Bernadinelli I; Laginha F; Boccardo E; Villa LL; Termini L; Lepique AP
PLoS One; 2019; 14(3):e0213184. PubMed ID: 30840689
[TBL] [Abstract][Full Text] [Related]
15. Multi-Omics Analysis Showed the Clinical Value of Gene Signatures of C1QC
Li X; Zhang Q; Chen G; Luo D
Front Immunol; 2021; 12():694801. PubMed ID: 34295336
[TBL] [Abstract][Full Text] [Related]
16. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
Zhang WY; Liu YJ; He Y; Chen P
J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
[TBL] [Abstract][Full Text] [Related]
17. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer.
Textor S; Dürst M; Jansen L; Accardi R; Tommasino M; Trunk MJ; Porgador A; Watzl C; Gissmann L; Cerwenka A
Int J Cancer; 2008 Nov; 123(10):2343-53. PubMed ID: 18712710
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiation therapy induces
Sood S; Patel FD; Srinivasan R; Dhaliwal LK
Indian J Med Res; 2018 Feb; 147(2):151-157. PubMed ID: 29806603
[TBL] [Abstract][Full Text] [Related]
19. IMAT-IGRT Treatment with Simultaneous Integrated Boost as Dose Escalation for Patients with Cervical Cancer: A Single Institution, Prospective Pilot Study.
Lőcsei Z; Sebestyén K; Sebestyén Z; Fehér E; Soltész D; Musch Z; Mangel LC
Pathol Oncol Res; 2021; 27():608446. PubMed ID: 34257570
[No Abstract] [Full Text] [Related]
20. Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells.
Street D; Kaufmann AM; Vaughan A; Fisher SG; Hunter M; Schreckenberger C; Potkul RK; Gissmann L; Qiao L
Gynecol Oncol; 1997 May; 65(2):265-72. PubMed ID: 9159336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
